🔍 Intelligence Synthesis JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes

AI and Cancer Research ── Breast ── 2026-09-30

A tissue slide overlaid by a translucent AI copy with glowing cell markers, nearly matching a hand-drawn ring but differing in a few places.
What this means, as an image (AI-generated, GPT Image): Where pathologists are scarce, AI TIL scoring can be considered as a prognostic aid, though not a replacement.Download image (PNG, 2000×800)
Diagram of three breast cancer papers. Pathologist scoring of tumour-infiltrating lymphocytes is reproducible but laborious. Locked AI models were deployed without retraining to quantify them, then tested in independent cohorts for links to survival and stratification of pertuzumab benefit. AI gave significant prognostic information but no incremental gain over pathologist scores. A separate preclinical path used histopathology foundation models to find poor-prognosis RNA-splicing archetypes.
Image abstract — the whole article on one page (click to enlarge)
3 Breast papers. Lead: Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

Journals covered and how papers are chosen: see the index

Breast cancer: treatment, trials and AI

← Back to this issue